Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Licenses Microarray Patents to Point Technologies

NEW YORK, June 24 -Incyte has licensed its microarray fabrication patents to Point Technologies, of Boulder, Colo., the companies said late Monday.


These patents, which Incyte has previously licensed to Agilent technologies, include US Patent No. 5,807,522, and US Patent No. 6,110,426. Both are entitled  "Methods for Fabricating Microarrays of Biological Samples," and cover the fabrication of a nucleic acid microarray by tapping the tip of a dispensing device against a solid support.


Point Technologies manufactures spotting pins for semiconductor manufacturing and microarray spotters. The patent licenses are intended to enable buyers of these spotting pins who use them in their own home-made microarraying devices, as well as those who manufacture arrayers, to use these pins for microarraying without infringing Incyte's patents, Point Technologies said.


Although Incyte continues to license out its microarray patents, the company exited the microarray manufacturing business in late 2001.


Separately, Incyte said today it had hired Richard De Schutter as chairman of its board of directors. De Schutter, a former chairman and CEO of DuPont, has served on Incyte's board since January 2002.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.